참고문헌
- Baker SD, Zhao M, Lee CK, et al (2004). Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res, 10, 1976-83. https://doi.org/10.1158/1078-0432.CCR-0842-03
- Berry W, Dakhil S, Gregurich MA (2001). Asmar L Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol, 28, 8-15. https://doi.org/10.1053/sonc.2001.26893
- de Bono JS, Logothetis CJ, Molina A, et al (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 364, 1995-2005. https://doi.org/10.1056/NEJMoa1014618
- de Bono JS, Oudard S, Ozguroglu M, et al (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 376, 1147-54. https://doi.org/10.1016/S0140-6736(10)61389-X
- Du LB, Li HZ, Wang XH, et al (2014). Analysis of cancer incidence in Zhejiang cancer registry in China during 2000 to 2009. Asian Pac J Cancer Prev, 15, 5839-43. https://doi.org/10.7314/APJCP.2014.15.14.5839
- Ferrero JM, Foa C, Thezenas S, et al (2004). A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology, 66, 281-7. https://doi.org/10.1159/000078328
- Messing EM, Manola J, Sarosdy M, et al (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341, 1781-8. https://doi.org/10.1056/NEJM199912093412401
- de Bono JS, Oudard S, Ozguroglu M, et al (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet, 376, 1147-54. https://doi.org/10.1016/S0140-6736(10)61389-X
- Garcia JA, Elson P, Tyler A, et al (2014). Sargramostim (GMCSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. Urol Oncol, 32, 11-7.
- Hurria A, Fleming MT, Baker SD, et al (2006). Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res, 12, 6100-5. https://doi.org/10.1158/1078-0432.CCR-06-0200
- Kantoff PW, Higano CS, Shore ND, et al (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 411-22. https://doi.org/10.1056/NEJMoa1001294
- Keizman D, Zahurak M, Sinibaldi V, et al (2010). Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res, 16, 5269-76. https://doi.org/10.1158/1078-0432.CCR-10-1928
- Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al (2013). 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol, 14, 117-24. https://doi.org/10.1016/S1470-2045(12)70537-5
- Luo HC, Cheng HH, Lin GS, et al (2013). Intensity-modulated radiotherapy combined with endocrine therapy for intermediate and advanced prostate cancer: long-term outcome of Chinese patients. Asian Pac J Cancer Prev, 14, 4711-5. https://doi.org/10.7314/APJCP.2013.14.8.4711
- Nabhan C, Petrylak DP (2012). The role of IMiDs alone or in combination in prostate cancer. Clin Genitourin Cancer, 10, 141-6. https://doi.org/10.1016/j.clgc.2012.03.005
- Nabhan C, Patel A, Villines D, et al (2014). Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study. Clin Genitourin Cancer, 12, 27-32. https://doi.org/10.1016/j.clgc.2013.09.001
- Nelson WG, De Marzo AM, Isaacs WB (2003). Prostate cancer. N Engl J Med, 349, 366-81. https://doi.org/10.1056/NEJMra021562
- Parker C, Nilsson S, Heinrich D, et al (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med, 369, 213-23. https://doi.org/10.1056/NEJMoa1213755
- Pazdur R (2013). FDA Approval for Docetaxel. Available:http://www.cancer.gov/cancertopics/druginfo/fda-docetaxel.
- Petrylak DP, Tangen CM, Hussain MH, et al (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351, 1513-20. https://doi.org/10.1056/NEJMoa041318
- Scher HI, Fizazi K, Saad F, et al (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 367, 1187-97. https://doi.org/10.1056/NEJMoa1207506
- Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166